{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:53:40Z","timestamp":1790970820881,"version":"4.1.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,2]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      This study investigates the role of cytochrome P450 2C19 (CYP2C19) gene polymorphisms and dyslipidaemic metabolism in ischemic cerebrovascular disease among Mongolian patients, analyzing their interaction with conventional risk factors. This case-control study enrolled 300 patients with ischemic cerebrovascular disease: 150 Mongolian patients (observation group) receiving CYP2C19 genotype-guided treatment and 150 Han Chinese patients (control group) undergoing standard care. Baseline characteristics, lipid profiles, CYP2C19 genotypes, NIHSS, and activities of daily living scores were analyzed. Baseline characteristics and CYP2C19 genotype distributions showed no significant differences between groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&gt;\u2005.05). Multivariate logistic regression revealed that the poor metaboliser phenotype significantly increased the risk of ischemic cerebrovascular disease odds ratio (OR)\u2005=\u20052.31, 95% confidence interval: 1.25\u20134.26,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.008), alongside hypertension (OR\u2005=\u20051.87,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.043) and diabetes mellitus (OR\u2005=\u20052.12,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.024). Dyslipidaemia prevalence was marginally but not significantly higher across genotypes in the Mongolian group. After 3 months of treatment, the genotype-guided observation group exhibited significantly greater reductions in total cholesterol and low-density lipoprotein cholesterol, and a slight increase in high-density lipoprotein cholesterol (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.05). Furthermore, the observation group demonstrated significantly superior neurological recovery National Institutes of Health Stroke Scale and improved daily functioning (ADL) compared to the control group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.001). CYP2C19 poor-metaboliser status is associated with an increased risk of ischemic cerebrovascular disease in the Mongolian population and may contribute to dyslipidaemia and treatment response heterogeneity. Individualised intervention guided by CYP2C19 genotyping offers potential benefits in improving lipid profiles, neurological function, and short-term outcomes, serving as a valuable tool for precision medicine in this population.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050807","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:01:23Z","timestamp":1790967683000},"page":"e50807","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Association of CYP2C19 genetic polymorphisms with dyslipidemia and ischemic cerebrovascular disease in the mongolian population"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9386-971X","authenticated-orcid":false,"given":"Gejile","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Neurology, Tongliao People\u2019s Hospital, Tongliao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9050-7849","authenticated-orcid":false,"given":"Jianhui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongliao People\u2019s Hospital, Tongliao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1662-3746","authenticated-orcid":false,"given":"Rui","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongliao People\u2019s Hospital, Tongliao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyang","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongliao People\u2019s Hospital, Tongliao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9202-6307","authenticated-orcid":false,"given":"Shiyang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongliao People\u2019s Hospital, Tongliao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2536-5346","authenticated-orcid":false,"given":"Baoqiang","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongliao People\u2019s Hospital, Tongliao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6255-358X","authenticated-orcid":false,"given":"Pengnan","family":"Bao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongliao People\u2019s Hospital, Tongliao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6500-3448","authenticated-orcid":false,"given":"Yue","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Baotou Central Hospital, Baotou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261002","doi-asserted-by":"crossref","first-page":"177546","DOI":"10.1016\/j.ejphar.2025.177546","article-title":"Effect of CYP2C19 genotype on outcomes of treatment with ticagrelor versus clopidogrel in acute coronary syndrome patients with diabetes mellitus: a analysis in a large-scale, real-world study.","volume":"996","author":"Tian","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"R2-20261002","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/jamaneurol.2020.3627","article-title":"A 5-decade analysis of incidence trends of ischemic stroke after transient ischemic attack: a systematic review and meta-analysis.","volume":"78","author":"Shahjouei","year":"2021","journal-title":"JAMA Neurol"},{"key":"R3-20261002","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jamaneurol.2019.2531","article-title":"Outcomes associated with clopidogrel-aspirin use in minor stroke or transient ischemic attack: a pooled analysis of Clopidogrel in HighRisk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trials.","volume":"76","author":"Pan","year":"2019","journal-title":"JAMA Neurol"},{"key":"R4-20261002","first-page":"6065","article-title":"The correlation between platelet responsiveness to clopidogrel and CYP2C19 polymorphism in patients with peripheral vascular disease.","volume":"25","author":"El-Khodary","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R5-20261002","doi-asserted-by":"crossref","first-page":"2526684","DOI":"10.1080\/0886022X.2025.2526684","article-title":"Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA stratified by age and renal function: CHANCE-2 trial substudy.","volume":"47","author":"Wu","year":"2025","journal-title":"Ren Fail"},{"key":"R6-20261002","doi-asserted-by":"crossref","first-page":"854280","DOI":"10.3389\/fmed.2022.854280","article-title":"CYP2C19 gene profiling as a tool for personalized stress ulcer prophylaxis with proton pump inhibitors in critically ill patients - recommendations proposal.","volume":"9","author":"Bo\u0159ilov\u00e1 Linhartov\u00e1","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R7-20261002","doi-asserted-by":"crossref","first-page":"23150","DOI":"10.1038\/s41598-021-02628-x","article-title":"Effect of CYP2C19 polymorphisms on serum valproic level acid in Chinese Han patients with schizophrenia.","volume":"11","author":"Wang","year":"2021","journal-title":"Sci Rep"},{"key":"R8-20261002","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00228-020-03050-4","article-title":"Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice.","volume":"77","author":"Russmann","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"R9-20261002","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s40262-019-00783-z","article-title":"Phenotyping of human CYP450 enzymes by endobiotics: current knowledge and methodological approaches.","volume":"58","author":"Magliocco","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"R10-20261002","doi-asserted-by":"crossref","first-page":"e28566","DOI":"10.1016\/j.heliyon.2024.e28566","article-title":"Genetic polymorphisms of CYP2C19 in ecuadorian population: an interethnic approach.","volume":"10","author":"Alonso Llorente","year":"2024","journal-title":"Heliyon"},{"key":"R11-20261002","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.15420\/ecr.2021.16.PO16","article-title":"Prevalence of aspirin and clopidogrel resistance in patients with recurrent ischaemic cerebrovascular disease.","volume":"16","author":"Karunawan","year":"2021","journal-title":"Eur Cardiol"},{"key":"R12-20261002","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/cpt.1973","article-title":"PharmVar GeneFocus: CYP2C19.","volume":"109","author":"Botton","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"R13-20261002","first-page":"13","article-title":"Safety of eptifibatide in addition to ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.","volume":"20","author":"Baharvand","year":"2025","journal-title":"J Tehran Univ Heart Cent"},{"key":"R14-20261002","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/jpm8010008","article-title":"Pharmacogenomic impact of CYP2C19 variation on clopidogrel therapy in precision cardiovascular medicine.","volume":"8","author":"Brown","year":"2018","journal-title":"J Pers Med"},{"key":"R15-20261002","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/FJC.0000000000001582","article-title":"Outcomes of ticagrelor versus high-dose clopidogrel in CYP2C19 intermediate metabolizer undergoing percutaneous coronary intervention for acute coronary syndromes.","volume":"84","author":"Huang","year":"2024","journal-title":"J Cardiovasc Pharmacol"},{"key":"R16-20261002","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s11033-024-10093-8","article-title":"CYP2C gene polymorphisms in North African populations.","volume":"51","author":"Messaoudi","year":"2024","journal-title":"Mol Biol Rep"},{"key":"R17-20261002","first-page":"4347","article-title":"Characteristics and predictors of cardiovascular events related to CYP2C19 gene polymorphisms following acute coronary syndrome.","volume":"28","author":"Tran","year":"2024","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R18-20261002","doi-asserted-by":"crossref","first-page":"300060520934657","DOI":"10.1177\/0300060520934657","article-title":"Association between CYP2C19 gene polymorphisms and lipid metabolism in Chinese patients with ischemic stroke.","volume":"48","author":"Bai","year":"2020","journal-title":"J Int Med Res"},{"key":"R19-20261002","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in cpatients at high cardiovascular risk: the STRENGTH randomized clinical trial.","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"R20-20261002","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk.","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"R21-20261002","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jacl.2023.03.009","article-title":"Remnant cholesterol and risk of myocardial infarction in patients with coronary artery disease undergoing revascularization.","volume":"17","author":"Zafrir","year":"2023","journal-title":"J Clin Lipidol"},{"key":"R22-20261002","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1136\/svn-2024-003293","article-title":"Dual antiplatelet therapy with ticagrelor vs clopidogrel in patients with TIA or minor stroke with or without symptomatic carotid artery stenosis: a post hoc analysis of the CHANCE-2 trial.","volume":"10","author":"Xie","year":"2025","journal-title":"Stroke Vasc Neurol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050807","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:01:27Z","timestamp":1790967687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050807"}},"subtitle":["A case-control study"],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":22,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050807","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"assertion":[{"value":"2025-12-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}